Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
| Image |  |
|---|---|
| Description | scientific article published on 8 July 2005 |
| Author/s |
author: Brian Schwartz |
| Publication date | July 8, 2005 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |